Product Description
Mechanisms of Action: DPD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fennec Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Triple Negative Breast Cancer
Phase 1: Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PCS6422-BC-01 | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-09-01 |
|
| PCS6422-GI-01 | P1 |
Completed |
Gastrointestinal Cancer |
2024-06-12 |